JenaValve Trilogy implantation abolished aortic regurgitation and improved LVAD efficiency in two patients despite valve closure and thrombotic sealing.
Does transfemoral JenaValve Trilogy implantation improve hemodynamics in LVAD patients with severe aortic regurgitation?
Transfemoral JenaValve Trilogy implantation provides hemodynamic benefit in LVAD patients with severe AR, even when functional or thrombotic valve closure occurs.
Absolute Event Rate: 0% vs 0%
Severe aortic regurgitation (AR) in patients with left ventricular assist device (LVAD) causes recirculatory flow and hemodynamic compromise. Two LVAD patients with severe AR underwent transfemoral JenaValve Trilogy implantation. Both procedures achieved immediate abolition of regurgitation; however, both prostheses subsequently showed valve closure, with one case progressing to complete thrombotic sealing. Despite closed prosthetic valves, both patients demonstrated improved LVAD efficiency and absence of clinical embolic events at last available follow-up. JenaValve Trilogy implantation can provide hemodynamic benefit in high-risk LVAD patients, even when functional or thrombotic valve closure occurs. However, long-term durability and anticoagulation strategies remain to be determined.
Bombace et al. (Sun,) reported a other. JenaValve Trilogy implantation abolished aortic regurgitation and improved LVAD efficiency in two patients despite valve closure and thrombotic sealing.